Press Releases

LAKE FOREST, Calif.--(BUSINESS WIRE)-- InSight Health Services Holdings Corp. ("Insight Imaging") (OTCBB: ISGT) announced today the appointment of Clark Nielsen as senior vice president - sales. Nielsen, who has extensive healthcare sales experience with Philips Healthcare, will have responsibility for sales of Insight Imaging's wholesale segment and will report directly to Kip Hallman, Insight Imaging's president and CEO.

"Clark's strong record of successfully leading sale teams in highly-competitive markets is exactly what Insight Imaging needs," said Mr. Hallman. "His demonstrated leadership skills and significant medical imaging experience increase our ability to meet the needs of our customers. We are extremely excited to have him on board with us."

Clark has more than 20 years of healthcare sales experience with Philips Healthcare, including leading strategic sales teams to some of the nation's most sophisticated healthcare providers. Most recently he served as Imaging Systems Region Sales Vice President, responsible for managing the Rocky Mountain Region.

Safe Harbor

The foregoing contains forward-looking statements regarding Insight Imaging. They reflect Insight Imaging's current views with respect to current events and financial performance, are subject to many risks, uncertainties and factors relating to Insight Imaging's operations and business environment which may cause the actual results of Insight Imaging to be materially different from any future results, express or implied by such forward-looking statements. Insight Imaging intends that such forward-looking statements be subject to the Safe Harbor created by Section 27(a) of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The words and phrases "expect," "estimate," and "anticipate" and similar expressions identify forward-looking statements. Certain factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: (i) Insight Imaging's ability to successfully implement its core market strategy; (ii) overcapacity and competition in Insight Imaging's markets; (iii) reductions, limitations and delays in reimbursement by third-party payors; (iv) contract renewals and financial stability of customers; (v) changes in the nature of commercial health care insurance arrangements, so that individuals bear greater financial responsibility through high deductible plans, co-insurance and co-payments; (vi) conditions within the healthcare environment; (vii) the potential for rapid and significant changes in technology and their effect on Insight Imaging's operations; (viii) operating, legal, governmental and regulatory risks; (ix) conditions within the capital markets, including liquidity and interest rates, and (x) economic (including financial and employment market conditions), political and competitive forces affecting Insight Imaging's business, and the country's economic condition as whole.

About Insight Imaging

Insight Imaging, headquartered in Lake Forest, Calif., is a provider of retail and wholesale diagnostic imaging services. Insight Imaging serves a diverse portfolio of customers, including healthcare providers, such as hospitals and physicians, and payors, such as managed care organizations, Medicare, Medicaid and insurance companies, in over 30 states, including the following targeted regional markets: California, Arizona, New England, the Carolinas, Florida and the Mid-Atlantic states.

For more information, please visit www.insighthealth.com.

    Source: Insight Imaging

- Stephen C. McCluski Named Chairman of the Board -

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, announced that Howard Pien was elected to its Board of Directors at today's Annual Meeting of Shareholders. The Company also announced that Stephen C. McCluski has been named Chairman of the Board, replacing former ImmunoGen CEO Mitchel Sayare, Ph.D., in this position. Dr. Sayare continues to serve on the Board as a director.

"We believe now is an appropriate time to realign our corporate governance structure and have a non-executive chairman," commented Daniel Junius, ImmunoGen President and CEO. "Steve has demonstrated that he can be an effective leader of the Board, and I look forward to working with him and the other directors in continuing to move the Company forward."

Mr. McCluski has served on the ImmunoGen Board of Directors since April 2007, bringing to it extensive business and financial expertise. He was the Senior Vice President and Chief Financial Officer of Bausch & Lomb Inc. prior to his retirement in 2007. Mr. McCluski is also a director of the James P. Wilmot Cancer Center of the University of Rochester and of Standard Microsystems Corporation.

"I look forward to serving ImmunoGen as chairman and - in this capacity - I am delighted to welcome Howard to the Board," commented Mr. McCluski. "Howard's experience at successful biotechnology and pharmaceutical companies will be invaluable as ImmunoGen continues to advance its pipeline."

Mr. Pien was the Chairman of the Board and CEO of Medarex, Inc. from 2007 to its acquisition by Bristol-Myers Squibb Company in September 2009. Prior to that, he was President and CEO of Chiron Corporation from 2003 to its acquisition by Novartis, and before that Mr. Pien held positions of increasing responsibility at GlaxoSmithKline and its predecessor, SmithKline Beecham, at Abbott Laboratories and at Merck & Co. He is also a director of ViroPharma Incorporated and Vanda Pharmaceuticals.

"ImmunoGen is transitioning to becoming an organization that not only does outstanding research but also successfully advances significant new anticancer therapeutics, and I am looking forward to serving on its Board," commented Mr. Pien.

At today's Annual Meeting, shareholders also voted to fix the number of members of the Board of Directors at nine and approved an amendment to the Company's restated articles of organization to increase the number of authorized shares of common stock from 75 million to 100 million shares. In addition to electing Mr. Pien and re-electing Mr. McCluski and Dr. Sayare to the Board, shareholders re-elected Mr. Daniel Junius, Mr. David Carter, Dr. Nicole Onetto, Mr. Mark Skaletsky, Dr. Joseph Villafranca and Mr. Richard Wallace to the Board.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

    Source: ImmunoGen, Inc.

NEWPORT NEWS, Va., Nov. 11, 2009 (GLOBE NEWSWIRE) -- Shipbuilders at Northrop Grumman Corporation's (NYSE: NOC) Shipbuilding sector in Newport News, Va., signed a 15-foot banner in preparation for the upcoming keel laying ceremony for the nuclear-powered aircraft carrier Gerald R. Ford (CVN 78). The banner will be on display at the ceremony on Nov. 14.

Photos accompanying this release are available at: http://media.globenewswire.com/noc/mediagallery.html?pkgid=6837

Susan Ford Bales, the daughter of the late President Gerald R. Ford, will serve as ship's sponsor and keel authenticator for the ceremony. Bales will authenticate the keel by chalking her initials onto a metal plate. Her initials will then be welded onto the plate.

Named after the 38th president of the United States, Gerald R. Ford (CVN 78) is the first ship of the new Gerald R. Ford class. The Ford class will continue the legacy of highly capable U.S. Navy nuclear-powered aircraft carrier ship platforms. Enhancements incorporated into the design include flight deck changes, improved weapons handling systems, and a redesigned island, all resulting in increased aircraft sortie rates. It will also include new nuclear power plants; increased electrical power generation capacity; allowance for future technologies; and reduced workload for the sailors, translating to a smaller crew size and reduced operating costs for the Navy.

Northrop Grumman Corporation is a leading global security company whose 120,000 employees provide innovative systems, products, and solutions in aerospace, electronics, information systems, shipbuilding and technical services to government and commercial customers worldwide.

CONTACT:  Jennifer Dellapenta
          Northrop Grumman Shipbuilding
          (757) 380-3558
          Jennifer.Dellapenta@ngc.com

TEMPE, Ariz.--(BUSINESS WIRE)-- Kinetic Muscles, Inc. ("KMI"), an innovative developer of stroke rehabilitation products, today announced the commercial launch of the Foot Mentor Pro(TM), which helps stoke survivors recover from "foot drop" and regain proper muscular control of the foot and ankle. Proper control of the lower extremity is essential to an efficient gait pattern for walking and for regaining patient independence.

Foot drop is a partial leg paralysis, caused by brain injury from stroke, traumatic brain injury and other conditions, that prevents the foot from lifting and flexing, causing instability and preventing patients from walking. According to the American Heart and Stroke Association, about 36% of stroke survivors suffer lasting impairment of their feet and legs.

Like the Hand Mentor Pro(TM), the Foot Mentor Pro(TM), uses proprietary video game technology at the patient interface in order to enable the cognitive engagement and extended, repetitive practice that have been shown by clinical studies to be critical to the recovery process. KMI's robotic technology, along with the proprietary patient interface and data communications module, promotes neuromuscular re-education through the clinically studied Active Repetitive Motion therapy that underlies KMI's product platform. The Foot Mentor Pro(TM) can be deployed in both the clinic and home settings. The device provides records of patient time spent on the device and progress against established clinical measures, thereby reducing costs by eliminating paper records and facilitating filing for reimbursement.

Dr. Kay Wing, DPT, owner of the SWAN Rehabilitation Clinic in Phoenix, led some of the early focus group studies of the Foot Mentor Pro, and she noted, "I am very encouraged by the early results of our focus group studies that pointed to notable improvements in foot and ankle mobility, along with better muscular control of foot flexion. I look forward to working with KMI to integrate the Foot Mentor Pro(TM) into our clinical practice for our patients."

About Kinetic Muscles, Inc.

Founded in 2001 in Tempe, Ariz., KMI is an innovative company that has leveraged groundbreaking research into neuroplasticity into a product platform that uses video game technology and robotics to provide Active Repetitive Motion(TM) therapy for patients suffering from stroke, traumatic brain injury, and other potential indications such as multiple sclerosis, incomplete spinal cord injury and cerebral palsy. Although its products incorporate high-technology, KMI's goal is to provide products that generate patient engagement in the home and clinic settings, encourage patient compliance with intensive therapy, and lower actual costs to the patient and to the healthcare system. KMI's first product, the Hand Mentor Pro(TM), is currently installed in approximately 100 leading rehabilitation clinics nationwide, and it has been the subject of several clinical studies by nationally recognized researchers.

    Source: Kinetic Muscles, Inc.

Hunter and Grimaud Amplify Firm's Reputable Auditing Services

SAN FRANCISCO & CAMPBELL, Calif.--(BUSINESS WIRE)-- Two seasoned audit partners, Dan Hunter and Steve Grimaud, have joined the accounting firm of Mohler, Nixon & Williams. Dan Hunter will strengthen the firm's reach into the San Francisco and North and East Bay markets, and Steve Grimaud will augment the firm's audit team in its Silicon Valley office. The addition of Dan Hunter and Steve Grimaud brings the total number of partners in the firm to 27, eleven partners in the audit practice.

"Dan and Steve are two talented professionals, and we are excited at what they bring to our practice," says Leinani Nakamura, CEO. "MNW's ability to continue to attract such knowledgeable partners from highly recognized firms is a result of our strong reputation for quality service in our markets," Nakamura says. "Our focus on client service attracts partners who share this value, and is the reason for our continued success."

Dan Hunter brings more than 18 years of accounting experience. Having served companies in high technology, manufacturing and distribution, software and services and clean tech for almost two decades, Dan Hunter offers Mohler, Nixon & Williams (MNW) clients a wealth of knowledge and experience. At MNW, Dan will specialize in auditing and accounting for private companies in the venture backed and middle market sectors. During his career, he has advised companies ranging from small, emerging businesses to large, multinational corporations. From this vast experience, he has gained a profound understanding of the wealth of business and accounting challenges facing today's rapidly growing companies, making him highly skilled at assisting clients in navigating the current complex business landscape.

Prior to joining MNW, Dan spent four years as an audit partner with BDO Seidman, LLP. Dan started his career with Ernst & Young, LLP, after graduating with a BA from UC Santa Barbara, and is an active a member of the AICPA and California Society of CPAs.

Steve Grimaud has over 25 years of professional experience and has worked with businesses based in the Silicon Valley for the last 22 years that range from privately held and venture backed entities to publicly held global enterprises. His experience is primarily from serving clients in the software, technology, manufacturing, distribution and service industries. He has assisted clients with initial public offerings, public and private debt offerings as well as with numerous SEC filings. Steve has also assisted many clients with mergers and acquisitions on both the buy and sell side.

Prior to joining MNW, Steve spent nine years as an audit partner with Deloitte & Touche LLP. He graduated with a BA from University of California Los Angeles. Steve is also a past president of the Silicon Valley San Jose Chapter of the California Society of CPAs and has been serving as the chapter's monthly bulletin editor for the past 10 years.

About MNW - Mohler, Nixon & Williams

Founded in 1980, MNW is one of the largest locally-based CPA firms in California, with 27 partners and more than 130 associates. MNW professionals help solve the business challenges of growing companies and the successful individuals who lead these companies. With offices in Silicon Valley, Palo Alto and San Francisco, we are consistently recognized as a nationally ranked Top 100 Firm and one of the Best Places to Work in the Bay Area.

For additional information, please visit www.mohlernixon.com.

    Source: Mohler, Nixon & Williams